BUSINESS● LOWAug 14 · Aug 14, 2026, 5:08 PM
Outlook Therapeutics targets more than $500M peak annual LYTENAVA sales by 2030 as it forecasts $50M-$75M first-year net revenue
Seeking Alpha Tech
Outlook Therapeutics is projecting significant peak annual sales for its product LYTENAVA by 2030 and forecasting first-year net revenue. This provides insight into the company's financial outlook and product performance expectations.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS20m agoGalleon Gold increases bought deal private placement of shares to $27MSeeking Alpha TechBUSINESS22m agoTech stocks had a nice oversold bounce on Monday. Earnings this week will determine if it's for realCNBC